Boston Scientific to Acquire Intera Oncology to Expand Interventional Oncology Portfolio with Intera 3000 Hepatic Artery Infusion Pump

"Cancer is the leading cause of cancer-related deaths, and we are committed to providing meaningful solutions to safely and effectively treat various forms of liver cancer, minimizing systemic side effects and improving patient outcomes. Due to technological advancements, positive clinical results, and ongoing trials, there is growing interest in HAI therapy within the oncology community. We believe this acquisition will enable us to offer a more comprehensive set of solutions for doctors and their patients to treat both primary and metastatic cancers."

According to data released by the National Cancer Center in 2022, there are up to 408,000 new cases of colorectal cancer patients annually in China, with 196,000 deaths. In the United States, there are 1.4 million patients with primary colorectal cancer, and an additional 150,000 new cases each year. Among these, about 25% of patients will develop liver metastases during their illness. The majority (80%-90%) of colorectal cancer patients with liver metastases initially have unresectable liver metastases. Liver metastasis is the leading cause of death for colorectal cancer patients. Statistics show that the median survival time for untreated liver metastasis patients is only 6.9 months, and the 5-year survival rate for unresectable patients is less than 5%.

For theseUntreated liver metastases orInoperableThe patient is somewhat at a loss in clinical practice. AndIntera OncologyDevelopmentTheIntera 3000Becoming the hope for these patients to survive.According toIntera OncologyDisclosure of clinical data shows:Intera 3000Clinical positive benefits for patients with unresectable colorectal liver metastases before HAI treatment.Compared with systemic chemotherapy, HAI treatment significantly improved tumor response, progression time, and overall survival. Combining HAI with systemic chemotherapy may extend the survival period for both chemotherapy-naive patients and those previously treated, while also increasing their resection conversion rate.

CurrentlyIntera 3000It is currently the only FDA-approved constant-flow implantable pump for hepatic artery infusion (HAI) therapy.

Boston Scientific, as a leader in the field of interventional oncology, has always hoped to save cancer patients through innovation. In recent years, it has continuously enriched its oncology product line through acquisitions, such as the acquisition of BTG in 2019 and Obsidio in 2022. Now, with another acquisition,Intera Oncology, making Boston Scientific the company with the most comprehensive interventional oncology solutions globally.

Intera 3000Consists of a pump capable of storing medication and a catheter connecting the pump to the hepatic artery.The pump is made of titanium., with a smooth outer surface. Other sizes are approximately the size of a human palm (diameter 7.6 cm),About 2.54 cm thick and weighs approximately 3 liang.

Once the pump is implanted in the patient's abdomen, it can rely on the patient's body temperature to drive drug delivery. Therefore, there is no possibility of failure due to battery, motor, or gear factors, or a decrease in pumping volume, providing consistently measured medication. The pump will not run out of power because it is powered by body heat.

Once the drug flows out of the storage chamber of the pump, it enters the catheter, then proceeds into the hepatic artery, and is directly delivered to the liver.

Intera OncologyIntera Oncology Inc. is an innovative medical device company headquartered in Boston. It was founded in 2019 by two doctors who share the vision of improving survival rates for patients with colorectal cancer liver metastases and bile duct cancer by ensuring access to hepatic artery infusion (HAI) therapy.Intera OncologyDedicated to changing the course of cancer through HAI therapy, helping patients live longer and better, thus creating the only FDA-approved HAI therapy pump---Intera 3000 。